SLC5A2 and type 2 diabetes mellitus: Two studies performed in T2DM patients with moderate renal impairment demonstrated that treatment with SGLT2 inhibitors led to an initial fall in estimated glomerular filtration rate (eGFR) with a trend toward an increase over time [28, 31].